URGO
 


Urgo Medical is a global wound care company offering a range of innovative dressings, compression bandaging and hosiery

 
 


 

NICE has released Medical Technology Guidance recommending the use of the UrgoStart Treatment Range for treating diabetic foot ulcers and venous leg ulcers1.

At any one time 115,000 people in the UK develop a diabetic foot ulcer (DFU), 2,3 and 278,000 people are treated for venous leg ulcers (VLU) every year.3 The cost of treating ulcers (leg, diabetic and pressure) is £3billion per year in the UK, rising to £15 billion when you consider additional social costs.4


The NICE guidance for UrgoStart1 states: ‘Evidence supports the case for the NHS adoption of UrgoStart dressings to treat diabetic foot ulcers and venous leg ulcers because they are associated with increased wound healing compared with non-interactive dressings.’


Cost modelling by NICE shows that, compared with standard care, using UrgoStart treatment is associated with an annual cost saving of £342 per patient for diabetic foot ulcers and £541 per patient for venous leg ulcers.1 Such cost savings are explained by a significant reduction in healing time, thus requiring fewer visits to hospital and from community nurses, reduced use of current dressings in managing wounds, and a reduction in social and health care costs. In addition, as healing time is reduced, there may be fewer wound-related complications (for example, amputations) further freeing up NHS staffing time and resources.
 

UrgoStart is the only effective local treatment proven to close more wounds and reduce healing time.5-8 It is now the recommended treatment choice of clinicians for all leg ulcers and diabetic foot ulcers.


Implementing UrgoStart dressings as part of an evidence-based treatment pathway is key to reducing healing time, releasing nursing time and resources, improving referral times and ensuring patients receive the highest quality of care. UrgoStart is a simple treatment that can easily be incorporated into your current standard of care and the Urgo Medical clinical team are available to fully support your local teams in implementing this new recommendation.

What do the experts say about the NICE recommendation for UrgoStart?


“This is tremendous news. Diabetes foot ulcers are extremely debilitating and can affect every aspect of the person’s life. Urgo Medical’s new treatment, which can significantly reduce the healing time of foot ulcers, will have a significant impact on thousands of patients living with this condition. The NICE guidance shows that UrgoStart can have a major impact on clinical outcomes and reduces costs for the NHS which is good news for both patients and healthcare professionals.”
Graham Bowen, Clinical Lead for Podiatry, Solent NHS Trust


“Patients really suffer both physically and psychologically when they develop an ulcer, significantly affecting their quality of life for many months and sometimes longer. If we can reduce the healing time by using the right dressings and treatments at the right time this will achieve the best outcome for the patient. NICE’s decision to support this standardised evidence-based approach to reducing the time to heal is great news for nurses as well, as it frees up our time to spend with other patients in need.”
Julie Mullings, Lead Nurse Tissue Viability, Manchester University NHS Foundation Trust


URGO TLC Logo


UrgoStart is a local treatment to reduce healing time with the unique TLC-NOSF Healing Matrix. It is available in a complete range for all your leg ulcer, diabetic foot ulcer, and pressure ulcer patients.

Urgo Start plus pad
TLC-NOSF Healing Matrix and poly-absorbent fibres (Pad format)
Urgo Start Plus Border TLC-NOSF Healing Matrix and poly-absorbent fibres (Absorbent border format)
Urgo Start Contact TLC-NOSF Healing Matrix (Contact layer format)
Urgo Start TLC-NOSF Healing Matrix (Absorbent foam format)
Urgo Start Border TLC-NOSF Healing Matrix (Absorbent foam border format)
  
To find out more about the full range, please visit:
www.urgostartplus.co.uk/urgostart-plus-range

Urgo Medical.  Healing People.


Urgo Medical is a global wound care company offering a range of innovative dressings, compression bandaging and hosiery.

Our focus is on working in partnership with healthcare professionals to help move from managing wounds to healing wounds using unique technologies and solutions. We believe strongly in evidence-based care, and pride ourselves on our products having the highest level of clinical evidence available to support their usage.

To help deliver improved patient outcomes and reduced healing time, we offer market-leading education and support through our experienced clinical team. If you would like support from the Urgo Medical team please contact your local Urgo Medical Representative or visit www.urgo.co.uk to find out more.




URGO-proving-life-changing-solutions-for-wound-healing
References:
  1. NICE Guidance Medical technology guidance: UrgoStart for treating diabetic foot ulcers and leg ulcers. Available at: www.nice.org.uk/guidance/mtg42. Last accessed February 2019.
  2. Kerr M. Diabetic Footcare in England: an economic study, January 2017. Insight Health Economics for Diabetes UK.
  3. Diabetes UK prevalence figures. Available at: www.diabetes.org.uk/professionals/position-statements-reports/statistics. Last accessed January 2019.
  4. Guest JF, Ayoub N, McIlwraith T et al. Health economic burden that different wound types impose on the UKs National Health Service. International Wound Journal. 2017. 6: 186-96.
  5. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G,Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196 Available at: www.ncbi.nlm.nih.gov/pubmed/29275068. Last accessed January 2019
  6. Meaume S, Truchetet F, Cambazard F, et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen 2012; 20: 4, 500–511
  7. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153
  8. Meaume S, Dompmartin A, Lazareth I, Sigal M, Truchetet F, Sauvadet A, Bohbot S. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7): 368-379.